These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 32134157)

  • 1. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
    Hou J; Deng Q; Zhou J; Zou J; Zhang Y; Tan P; Zhang W; Cui H
    Oncogene; 2017 Feb; 36(8):1134-1144. PubMed ID: 27546621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of EGFR, ERK-1,2 and AKT-1,2 Activity on Human Glioma Cell Growth.
    Alahverdi A; Arefian E; Soleimani M; Ai J; Yousefi-Ahmadipour A; Babaei A; Islam MS; Ebrahimi-Barough S
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3469-3475. PubMed ID: 33369441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
    Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
    Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
    Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
    J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
    Song X; Shao Y; Jiang T; Ding Y; Xu B; Zheng X; Wang Q; Chen X; Gu W; Wu C; Jiang J
    EBioMedicine; 2018 Feb; 28():105-113. PubMed ID: 29396299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
    Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
    Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
    Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
    Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
    Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
    Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.